The effectiveness of cytoprotection in the treatment of stable angina in patients with arterial hypertension and hyperuricemia, taking into account the peculiarities of the course of coronary artery disease in wartime

Authors

DOI:

https://doi.org/10.15587/2519-4798.2022.268523

Keywords:

cytoprotection, stable angina pectoris, hyperuricemia, coronary artery disease, wartime, arterial hypertension

Abstract

The aim of the study is to establish the effectiveness of treatment of severe angina pectoris in patients with hyperuricemia, taking into consideration the peculiarities of the course of coronary artery disease (CAD) in wartime, using ranolazine – a selective inhibitor of the late sodium flow in combined pharmacotherapy.

Materials and methods. We studied the anti-anginal effect of ranolazine in 14 patients with CAD, stable angina pectoris III-IV functional class (FC), hyperuricemia and arterial hypertension (AH) during 6 months of the 2022 year. The effectiveness of the study drug on the clinical course of angina pectoris was assessed by questionnaire and clinical examination after three months of treatment.

The results. At the end of the second week of ranolazine use, angina attacks at rest, which were registered before the start of the observation, stopped in all patients with angina pectoris III FC and 50 % with angina pectoris IV FC. In 78.6 %, the number of angina attacks and the use of nitrates decreased by more than 2 times; 21.4 % no longer had angina attacks.

At the end of the first month, anginal attacks were not observed in all patients with angina pectoris III FC and 50 % with angina pectoris FC IV. In 2 patients with angina pectoris IV FC (50 %), anginal attacks continued to be registered during physical exertion and emotional stress, but no more than once a week. At the same time, there were no angina attacks at rest. The same results were obtained during the survey of patients at the end of three months of observation.

Conclusions. Ranolazine is an effective component of anti-anginal therapy, significantly affecting the patient's quality of life. Therefore, we can recommend ranolazine for patients with hyperuricemia in angina attacks that persist with insufficient effectiveness of zasic therapy with first-line drugs, especially during military conflicts

Author Biographies

Victoriia Iablonska, Odesa National Medical University

Doctor of Philosophy, Associate Professor

Department of Internal Medicine No. 2

Center of Reconstructive and Restorative Medicine (University Clinic)

Leonid Kholopov, Odesa National Medical University

Doctor of Philosophy, Associate Professor

Department of Internal Medicine No. 2

Center of Reconstructive and Restorative Medicine (University Clinic)

Olena Khyzhnyak, Odesa National Medical University

Doctor of Philosophy, Associate Professor

Department of Internal Medicine No. 2

Center of Reconstructive and Restorative Medicine (University Clinic)

Viktoriia Batashova-Halinska, Odesa National Medical University

Doctor of Philosophy, Associate Professor

Department of Internal Medicine No. 2

Center of Reconstructive and Restorative Medicine (University Clinic)

References

  1. Batelaan, N. M., Seldenrijk, A., van den Heuvel, O. A., van Balkom, A. J. L. M., Kaiser, A. et al. (2022). Anxiety, Mental Stress, and Sudden Cardiac Arrest: Epidemiology, Possible Mechanisms and Future Research. Frontiers in Psychiatry, 12. doi: https://doi.org/10.3389/fpsyt.2021.813518
  2. Ismaiel, A., Spinu, M., Leucuta, D.-C., Popa, S.-L., Chis, B. A., Fadgyas Stanculete, M. et al. (2022). Anxiety and Depression in Metabolic-Dysfunction-Associated Fatty Liver Disease and Cardiovascular Risk. Journal of Clinical Medicine, 11 (9), 2488. doi: https://doi.org/10.3390/jcm11092488
  3. Ghosh, G., Ghosh, R., Bandyopadhyay, D., Chatterjee, K., Aneja, A. (2018). Ranolazine: Multifaceted role beyond coronary artery disease, a recent perspective. Heart Views, 19 (3), 88–98. doi: https://doi.org/10.4103/heartviews.heartviews_18_18
  4. Kaplan, A., Amin, G., Abidi, E., Altara, R., Booz, G. W., Zouein, F. A. (2022). Role of ranolazine in heart failure: From cellular to clinic perspective. European Journal of Pharmacology, 919, 174787. doi: https://doi.org/10.1016/j.ejphar.2022.174787
  5. Maulana, S., Nuraeni, A., Aditya Nugraha, B. (2022). The Potential of Prognostic Biomarkers of Uric Acid Levels in Coronary Heart Disease Among Aged Population: A Scoping Systematic Review of the Latest Cohort Evidence. Journal of Multidisciplinary Healthcare, 15, 161–173. doi: https://doi.org/10.2147/jmdh.s340596
  6. Andrievskaya, S. A., Krotenko, V. K., Kolesnik, V. A. (2019). New components of contemporary arrhythmology – the basics of pathogenesis and their clinical justification. Medicine of Ukraine, 8 (234), 16–23. doi: https://doi.org/10.37987/1997-9894.2019.8(234).187158
  7. Cattaneo, M., Halasz, G., Cattaneo, M. M., Younes, A., Gallino, C., Sudano, I., Gallino, A. (2022). The Central Nervous System and Psychosocial Factors in Primary Microvascular Angina. Frontiers in Cardiovascular Medicine, 9. doi: https://doi.org/10.3389/fcvm.2022.896042
  8. Kofler, T., Hess, S., Moccetti, F., Pepine, C. J., Attinger, A., Wolfrum, M., Toggweiler, S., Kobza, R., Cuculi, F., Bossard, M. (2021). Efficacy of Ranolazine for Treatment of Coronary Microvascular Dysfunction—A Systematic Review and Meta-analysis of Randomized Trials. Canadian Journal of Cardiology, 3 (1), 101–108. doi: https://doi.org/10.1016/j.cjco.2020.09.005
  9. Sharp, R. P., Patatanian, E., Sirajuddin, R. (2021). Use of Ranolazine for the Treatment of Coronary Microvascular Dysfunction. American Journal of Cardiovascular Drugs, 21 (5), 513–521. doi: https://doi.org/10.1007/s40256-020-00462-6
  10. Cho, S.-G., Kim, H. Y., Bom, H.-S. (2020). Anxiety as a risk factor in coronary artery disease among young women. Journal of Nuclear Cardiology, 28 (6), 2593–2596. doi: https://doi.org/10.1007/s12350-020-02101-8
  11. He, C., Zhu, C., Han, B., Hu, H., Wang, S., Zhai, C., Hu, H. (2020). Association between anxiety and clinical outcomes in Chinese patients with myocardial infarction in the absence of obstructive coronary artery disease. Clinical Cardiology, 43 (7), 659–665. doi: https://doi.org/10.1002/clc.23386
  12. Knuuti, J., Wijns, W., Saraste, A., Capodanno, D., Barbato, E., Funck-Brentano, C. et al. (2019). ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology. European Heart Journal, 41 (3), 407–477. doi: https://doi.org/10.1093/eurheartj/ehz425
  13. Rosano, G. M., Vitale, C. (2018). Metabolic Modulation of Cardiac Metabolism in Heart Failure. Cardiac Failure Review, 4 (2), 99–103. doi: https://doi.org/10.15420/cfr.2018.18.2
  14. Volynskyi, D., Vakaliuk, I. (2019). Use of meldonium in the treatment of patients with coronary artery disease and concomitant arterial hypertension. EUREKA: Health Sciences, 6, 9–14. doi: https://doi.org/10.21303/2504-5679.2019.001018
  15. Salazar, C. A., Basilio Flores, J. E., Veramendi Espinoza, L. E., Mejia Dolores, J. W., Rey Rodriguez, D. E., Loza Munárriz, C. (2017). Ranolazine for stable angina pectoris. Cochrane Database of Systematic Reviews, 2019 (1). doi: https://doi.org/10.1002/14651858.cd011747.pub2
  16. Zweiker, R., Aichinger, J., Metzler, B., Lang, I., Wallner, E., Delle-Karth, G. (2019). Ranolazine: impact on quality of life in patients with stable angina pectoris, results from an observational study in Austria – the ARETHA AT study. Wiener Klinische Wochenschrift, 131 (7-8), 165–173. doi: https://doi.org/10.1007/s00508-019-1481-x
  17. Leelapatana, P., Thongprayoon, C., Prasitlumkum, N., Vallabhajosyula, S., Cheungpasitporn, W., Chokesuwattanaskul, R. (2021). Role of Ranolazine in the Prevention and Treatment of Atrial Fibrillation in Patients with Left Ventricular Systolic Dysfunction: A Meta-Analysis of Randomized Clinical Trials. Diseases, 9 (2), 31. doi: https://doi.org/10.3390/diseases9020031

Downloads

Published

2022-11-30

How to Cite

Iablonska, V., Kholopov, L., Khyzhnyak, O., & Batashova-Halinska, V. (2022). The effectiveness of cytoprotection in the treatment of stable angina in patients with arterial hypertension and hyperuricemia, taking into account the peculiarities of the course of coronary artery disease in wartime. ScienceRise: Medical Science, (6 (51), 4–7. https://doi.org/10.15587/2519-4798.2022.268523

Issue

No. 6 (51) (2022)

Section

Medical Science

License

Copyright (c) 2022 Victoriia Iablonska, Leonid Kholopov, Olena Khyzhnyak, Viktoriia Batashova-Halinska

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.

Authors, who are published in this journal, agree to the following conditions:

1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.

 2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.